Metropolis Healthcare IPO description – Metropolis Healthcare is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan). The company has widespread presence across 18 states in India, with leadership position in west and south India. Through its widespread operational network, Metropolis Healthcare offers a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. The company also offers analytical and support services to clinical research organizations for their clinical research projects. During the financial year 2018, it conducted approximately 16.0 million tests from approximately 7.7 million patient visits.
The company offers a broad range of approximately 3,480 clinical laboratory tests and 524 profiles. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. Its tests are classified in three categories – (i) ‘routine’ tests such as blood chemistry analyses, blood cell counts and urine examination; (ii) ‘semi-specialized’ tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and (iii) ‘specialized’ tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics.
Promoters of Metropolis Healthcare – Dr Sushil Kanubhai Shah, Ameera Sushil Shah and Metz Advisory LLP
| Metropolis Healthcare IPO details | |
| Subscription Dates | 3 – 5 April 2019 |
| Price Band | INR877 – 880 per share |
| Fresh issue | Nil |
| Offer For Sale | 13,685,095 shares (INR1,200.2 – 1,204.29 crore) |
| Total IPO size | 13,685,095 shares (INR1,200.2 – 1,204.29 crore) |
| Minimum bid (lot size) | 17 shares |
| Face Value | INR2 per share |
| Retail Allocation | 10% |
| Listing On | NSE, BSE |
| Metropolis Healthcare’s financial performance (in INR crore) | ||||||
| FY2016 | FY2017 | FY2018 | 9M FY2019 | |||
| Total revenues | 490.6 | 567.7 | 651.6 | 566.8 | ||
| Total expenses | 366.4 | 410.4 | 491.3 | 431.2 | ||
| Comprehensive income | 80.0 | 107.5 | 110.5 | 90.6 | ||
| Net margin (%) | 16.3 | 18.9 | 17.0 | 16.0 | ||
More about Metropolis Healthcare
- Metropolis Healthcare IPO recommendations: Subscribe or Avoid?
- Metropolis Healthcare IPO: 5 things you need to know
Metropolis Healthcare Contact Details
Metropolis Healthcare LimitedÂ
250 D Udyog Bhavan, Hind Cycle Marg,
Worli, Mumbai 400 030
Phone:Â +91 22 6258 2810
Email: [email protected]
Website:Â www.metropolisindia.com
Registrar of Metropolis IPO
Link Intime India Private Limited
C-101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email:Â [email protected]
Website:Â http://www.linkintime.co.in
Valuation of Metropolis Healthcare (FY2018)
Earnings Per Share (EPS): INR20.49
Price/Earnings (PE ratio): 42.80-42.95
Return on Net Worth (RONW): 24.66%
Net Asset Value (NAV): INR83.58 per share
Metropolis Healthcare IPO Subscription Details
| Category | Shares offered | Subscription (no. of times) | ||
| Day 1 | Day 2 | Day 3 | ||
| QIB | 4,015,529 | 0.09 | 0.64 | 9.07 |
| NII | 2,007,764 | 0.00 | 0.01 | 3.03 |
| Retail | 1,338,509 | 0.25 | 0.69 | 2.03 |
| Employees | 300,000 | 0.00 | 0.01 | 0.05 |
| Total | 7,661,802 | 0.09 | 0.46 | 5.80 |
Metropolis Healthcare IPO Allotment Status
Metropolis Healthcare IPO allotment status is now available on Link Intime’s website. Click on this link to get allotment status.
Listing Performance of Metropolis Healthcare Limited
IPO Opening Date: 3 April 2019
IPO Closing Date: 5 April 2019
Finalisation of Basis of Allotment: 10 April 2019
Initiation of refunds: 11 April 2019
Transfer of shares to demat accounts: 12 April 2019
Listing Date: 15 April 2019
Listing Price on NSE: INR958 per share (up 8.86% from IPO price)
Closing Price on NSE:Â INR959.85 per share (up 9.07% from IPO price)
Good company ipo after a long time
How is it good? I think it is expensive when compared to its competitors like Thyrocare.